Antibodies Against Membrane Protein Targets - Part 1 Header


As the pharmaceutical and biotech industries increasingly shift attention to biologics, much more attention is being paid to the prospect of membrane-bound proteins as drug targets for antibodies and other protein scaffolds. For the large GPCR and ion channel target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs and the potential for using antibodies for the targeted delivery of therapeutics. However, for the field to advance, fundamental challenges in optimizing antigen quality and presentation, discovery methodologies, protein engineering and target identification must be resolved.

This two-part meeting provides a forum in which discovery biologists and protein engineers can come together to discuss next generation strategies and technologies that will allow antibody- and alternate scaffold-based therapeutics directed against these target families to advance into the clinic and beyond.

Part One:

The first meeting in the set, Antigen Optimization and Antibody Generation, offers a comprehensive examination of state of the art approaches for producing high quality membrane protein antigens and the display and immunization strategies that can be applied to discover binders with functional activity against GPCR and ion channel targets.

Preliminary Agenda


EXPRESSION AND PRODUCTION OPTIMIZATION OF MEMBRANE PROTEIN ANTIGENS

GPCR Solubilization

Jeffery G. Saven, Ph.D., Professor of Chemistry, University of Pennsylvania

Stabilization of Functional Membrane Proteins Using Lipid-Like Self-Assembling Peptides

Sotirios Koutsopoulos, Ph.D., Research Scientist, Center for Biomedical Engineering, Massachusetts Institute of Technology

Methods and Strategies to Deliver Ion Channel Reagents for Antibody Discovery

Michael Mullin, Ph.D., Investigator, GlaxoSmithKline

A Saposin-Based Nanoparticle System for Stabilization of Membrane Proteins

Jens Frauenfeld, Ph.D., CEO, Salipro Biotech AB


ANTIBODY GENERATION AND ENGINEERING STRATEGIES

Generation of Synthetic Antibodies to Trap Functional Intermediates of Membrane Proteins

Tony Kossiakoff, Ph.D., Professor, Biochemistry & Molecular Biophysics, University of Chicago

Generation of Functional Antibodies Against the P2X3 Ion Channel

Lili Huang, M.D., Ph.D., Principal Research Scientist, AbbVie

Inducible GPCR Cell Lines for Antibody Characterization

Eric Grazzini, Ph.D., Senior Research Officer, Biologics, National Research Council of Canada

Generation of Functional mAbs Targeting GPCRs for Fibrosis and Autoimmune Disease Indications

Kiyoshi Takayama, Ph.D., President, Research Center, NB Health Laboratory Co., Ltd.


NEW TECHNOLOGIES FOR DISCOVERY OF ANTIBODIES AGAINST MEMBRANE PROTEIN TARGETS

Cell Surface Panning

David M. Kranz, Ph.D., Professor, Biochemistry, University of Illinois, Urbana-Champaign

New Strategies and Technologies for Ab Discovery without Purified Proteins

JT Koerber, Ph.D., Scientist, Antibody Engineering, Genentech

Rapid Identification of High Affinity mAbs for Multi-TM Targets Using Live Cells

Martin Scott, Ph.D., Investigator, GlaxoSmithKline

Nanobody Scaffold Platform

Roger Dawson, Ph.D., Discovery Technologies, F. Hoffmann-La Roche AG

Discovery and Development of Antibody Therapeutics Against GPCR Targets

John Burg, Ph.D., Director, Antibody Development, Ab Initio Biotherapeutics




For questions or suggestions about the meeting, please contact:
Kent Simmons
Producer
Cambridge Healthtech Institute
T: (+1) 781-972-9199
E: ksimmons@healthtech.com

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com